Vedolizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Vedolizumab
- Vedolizumab: From Inflammatory Bowel Disease to Severe Nonproliferative Diabetic Retinopathy
Vedolizumab: From Inflammatory Bowel Disease to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Vedolizumab is a gut-selective α4β7 integrin antagonist used for the treatment of inflammatory bowel disease (Crohn’s disease and ulcerative colitis), based on the literature contained in this evidence pack. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but currently 0 clinical trials and 0 publications support this specific prediction — it is a pure AI model output with no mechanistic or clinical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in EU regulatory data (no marketing authorizations on file); literature identifies inflammatory bowel disease (Crohn’s disease, ulcerative colitis) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 94.51% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the regulatory record for this candidate (flagged as a High-severity data gap). Based on the literature retrieved in this evidence pack, vedolizumab is a humanized monoclonal antibody that binds integrin α4β7 and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is expressed specifically in the small intestine and colon. This gut-selective mechanism restricts lymphocyte trafficking to the gastrointestinal mucosa and underlies its established efficacy in Crohn’s disease and ulcerative colitis.
For the top-ranked predicted indication, severe nonproliferative diabetic retinopathy, there is no known biological or mechanistic pathway connecting gut-selective α4β7/MAdCAM-1 blockade to retinal microvascular disease. The evidence pack’s own rationale for this pairing states explicitly that this is a pure TxGNN model output with no clinical or literature support — the association appears to be a topological/embedding artifact rather than a biologically grounded hypothesis.
It is worth noting that lower-ranked candidates in this pack (e.g., dermatitis, bronchitis) do have some literature signal, but that signal is uniformly safety-related (case reports of vedolizumab-induced skin eruptions, and a respiratory-infection safety analysis) rather than evidence of therapeutic benefit — it should not be misread as supporting repurposing toward those indications either.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Vedolizumab currently has no EU marketing authorization on file in this dataset (market status: Not Marketed; 0 authorizations recorded).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (severe nonproliferative diabetic retinopathy) has no clinical trials, no literature, and no plausible mechanistic link to vedolizumab’s known gut-selective mode of action — it meets the definition of an L5, model-only prediction. Combined with the absence of any EU marketing authorization and a blocking data gap on regulatory safety labeling, there is no basis to advance this candidate beyond hypothesis stage.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (blocking gap, required before any S1 safety screening)
- Confirmed mechanism-of-action documentation (High-severity gap)
- Preclinical or mechanistic studies establishing a biological rationale linking α4β7/MAdCAM-1 blockade to retinal microvascular disease
- Any prospective clinical or case-level evidence for this specific indication pairing before moving past S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.